Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma
Real-world data confirms brexu-cel delivers strong responses in treatment-resistant lymphoma, with early signs that blood counts might predict who needs closer toxicity monitoring.
Austrian multicenter real-world data (n=33) confirms high ORR (95.9%) and OS (76.8% at 2yr) with brexu-cel in r/r MCL, aligning with pivotal trial outcomes. An exploratory finding suggests pre-lymphodepletion leukocyte and neutrophil counts may predict toxicity severity, offering a practical pre-treatment biomarker signal.
What the study was
- Study design
- Retrospective real-world cohort
- Population
- Adult patients with r/r MCL enrolled in Austrian national CAR-T program 2021-Jan 2025
- Sample size
- 33
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
Real-world CAR-T data in rare B-cell malignancy; confirms pivotal trial efficacy; novel biomarker hypothesis for toxicity prediction is noteworthy but limited by n=33 and retrospective design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.